GlassScriptPhysician profile
Raymond Th Lee
NPI 1356754360
$2,809.83
in general payments reported to CMS, 2019-2025
27 companies · $1,329 in 2025
The $1,329 reported for 2025 was more than what a typical Transplant Hepatology provider received nationally (typical 2025 total: $508).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $185 · 2022: $236 · 2023: $202 · 2024: $627 · 2025: $1,329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,157.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $450.29 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $273.19 | 2019-2025 | Entyvio, Livtencity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $263.17 | 2020-2023 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $239.40 | 2022-2025 | Ocaliva |
| Janssen Biotech, INC. | $182.96 | 2019-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $181.50 | 2025 | |
| Novo Nordisk INC | $170.68 | 2022-2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $162.76 | 2024-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $145.92 | 2025 | Iqirvo |
| Abbvie INC. | $107.75 | 2019-2024 | |
| Madrigal Pharmaceuticals | $79.44 | 2025 | Rezdiffra |
| Eisai INC. | $65.54 | 2024 | |
| Covidien LP | $65.00 | 2019 | |
| Phathom Pharmaceuticals, INC. | $63.83 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $57.59 | 2024-2025 | Dificid, Prevymis, Zerbaxa |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $56.61 | 2024 | |
| Genentech USA, INC. | $29.84 | 2025 | Tecentriq |
| Otsuka America Pharmaceutical, INC. | $29.73 | 2024 | Jynarque |
| Daiichi Sankyo INC. | $26.97 | 2024 | Injectafer |
| Veloxis Pharmaceuticals, INC. | $23.74 | 2024 | Envarsus |
| Evoke Pharma, INC. | $22.67 | 2024 | |
| Blue Earth Diagnostics | $22.35 | 2022 | |
| Exelixis INC. | $21.94 | 2024 | Cabometyx |
| Vivus LLC | $21.66 | 2024 | Qsymia |
| Orphalan INC | $16.58 | 2025 | Cuvrior |
| Shire North American Group INC | $14.79 | 2019 | |
| Eurofins Viracor, LLC | $13.93 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.